Thalia Therapeutics Plc (FRA:0GO)

Germany · Delayed Price · Currency is EUR

0.0080

0.00 (0.00%)

Last updated: Aug 27, 2026, 8:03 AM CET

700.00% (1Y)

Market Cap	6.32M +31.6%
Revenue (ttm)	8.33K -0.2%
Net Income	-1.38M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0080
Previous Close	0.0080
Day's Range	0.0080 - 0.0080
52-Week Range	0.0005 - 0.0265
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 25, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation in... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 1979

Employees 3

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 0GO

Financial Performance

In 2025, Thalia Therapeutics's revenue was 7,264, a decrease of -0.25% compared to the previous year's 7,282. Losses were -1.21 million, 13.8% more than in 2024.

Financial numbers in GBP Financial Statements